MARLBOROUGH, Mass., Oct. 12, 2011 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight™ Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that its HeartLight EAS was used to achieve successful acute PV isolation and restore sinus rhythm in a persistent AF patient during a live case at the Venice Arrhythmias 2011 conference, October 9-12 in Venice, Italy.
Additionally, research presented during the scientific sessions further supports the ability of the compliant balloon system to accommodate varied vein anatomy with a single catheter, achieving 99% acute isolation irrespective of vein size and shape.
"The live case outcome and clinical findings presented at the conference are exciting, as they've revealed the HeartLight EAS may be suitable for a larger sub-set of patients who are otherwise unable to be treated with a single ablation catheter. We are pleased that research continues to instill confidence in the technology and support its versatile clinical use," said Stephen Sagon, President and CEO of CardioFocus.
In the live case, physicians successfully isolated all four PVs of a patient with persistent AF and restored the patient to normal sinus rhythm. The procedure was performed by leading electrophysiologists Sakis Themistoclakis, MD, of Dell'Angelo Hospital and Andrea Natale, MD, of Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Austin, Texas. The session was chaired by Petr Neuzil, MD, of Na Homolce Hospital, Prague, Czech Republic.
To perform the case, the physicians employed the new HeartLight EAS handle configuration for the first time in Italy. The enhanced handle was designed for single-handed control of both catheter manipulation and the location of energy delivery to improve procedural efficiency.
Dr. Themistoclakis commented, "The HeartLight EAS compliant balloon catheter allows for very good contact with all PVs to deliver